 |
Summaries of news from MS websites around the world. Links will take you to the source articles.
If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate
MS Society of Canada to host a webcast on CCSVI
The Multiple Sclerosis Society of Canada will be holding a webcast for the public and the media on the topic of chronic cerebrospinal venous insufficiency (CCSVI) and MS.
Fast Forward call for proposals
Fast Forward, the commercial drug development arm of the US National MS Society, has issued a call for research proposals for novel therapeutic approaches to prevent, treat or reverse nervous system damage in MS.
Canada ratifies UN Convention on the Rights of Persons with Disabilities
On 11 March 2010, Canada, with the support of all provinces and territories, ratified the United Nations Convention on the Rights of Persons with Disabilities.
Epstein-Barr virus update
Researchers have observed for the first time that the risk of MS increases following infection with the Epstein-Barr virus (EBV). This finding implicates EBV as a contributory cause to MS.
Success for UK pilot scheme
The UK Relapse Support Service, which enables people with MS to get financial support when they experience a relapse, has had positive results. This pilot scheme, run jointly by the UK MS Society, East Sussex County Council, and WELbeing, is the first of its kind in the UK.
LDN phase II trial results published
Results of a phase II clinical trial on the safety and effectiveness of low dose naltrexone (LDN) as a symptom-relief treatment for people with MS have been published in the journal Annals of Neurology.
Stanford University halts CCSVI treatments after two serious incidents
Researchers at Stanford University, USA, have halted treatments for chronic cerebrospinal venous insufficiency (CCSVI) according February's edition of the journal Annals of Neurology.
Ampyra – video webcast now available
Ampyra, the first therapy specifically approved to treat a symptom of MS, is now available in the US on prescription. The US National MS Society have produced a video webcast including information about this therapy and who can take it.
First glimpse of MS studies to be presented at AAN meeting
The American Academy of Neurology (AAN) has issued press releases about two MS studies: "Drinking milk during pregnancy may lower baby's risk of MS" and "Migraine more common in women with MS," which will be presented at the ANN annual meeting in Toronto, Canada, 10-17 April, 2010.
Gilenia receives priority review from FDA
Gilenia, the oral drug for relapsing MS formerly known as FTY720, has been granted priority review by the US Food and Drug Administration (FDA). An approval decision could take as little as six months.
|
